Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03097315) enrolled 38 adults who received a 4 mg injection of a medicine called CLS-TA delivered into a specific layer at the back of the eye (the suprachoroidal space). The trial was studying a condition called uveitis — inflammation inside the eye — and was measuring things like unwanted medical events (adverse events), eye pressure, and several signs of eye inflammation at different points in time. The reported data shows that 27 out of 38 participants experienced at least one treatment-emergent adverse event (an unwanted medical event that occurred after receiving the injection), and 1 participant experienced a serious adverse event (a more severe medical event meeting specific criteria such as requiring hospitalisation). Regarding eye pressure, the reported average was 13.3 mmHg at one time point and 15.2 mmHg at another (normal eye pressure is generally considered to be in a range up to around 21 mmHg, though this trial did not report a comparison figure). For the inflammation measures, the number of participants recorded as having the lowest possible inflammation score (grade 0 — meaning little to no detectable inflammation) increased between the two reported time points: for inflammatory cells in the front of the eye, this went from 17 to 31 participants; for fluid-related inflammation in the front of the eye ("flare"), from 27 to 34 participants; and for haziness in the centre of the eye, from 17 to 34 participants. The trial did not report whether these changes were statistically meaningful, and no comparison group was included in this single-group study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36787524) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with uveitis (inflammation inside the eye) — either currently active or not currently active — that is not caused by an infection. This includes uveitis affecting different parts of the eye (front, middle, back, or the whole eye).
- You are able to read at least 5 letters on a standard eye chart with the eye being studied in the trial.
Who may not be able to join:
- You have another active eye disease or eye infection (other than uveitis) in the eye being studied.
- The pressure inside your study eye is too high (above 22 mmHg), or you have glaucoma that is not well controlled. However, you may still be eligible if your eye pressure is 22 or below and you are using no more than 2 eye-pressure-lowering medications.
- You have another serious health condition that is not well controlled, which the trial doctor feels would make it unsafe for you to participate.
- You have received certain steroid treatments to or near the study eye recently — specifically: steroid eye drops within the last 10 days, steroid injections in or around the eye within the last 2 months, an OZURDEX implant within the last 6 months, or a RETISERT or ILUVIEN implant within the last 3 years (confirm with trial site if you are unsure which treatments you have received).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.